September 13, 2021

ASCO Clinical Panel Series: DLBCL

June 8, 2021

ASCO Clinical Panel Series: DLBCL


LARVOL is pleased to present a moderated discussion with top oncologists following ASCO's Annual Meeting 2021. In the video below, Dr. Kevin Knopf, Dr. Aaron Goodman, and Dr. Jordan Gauthier discuss the practice-changing impact of ASCO presentations in DLBCL.

On June 7, 2021, LARVOL hosted an Oncology Panel to discuss the top diffuse large B-cell lymphoma (DLBCL) clinical trial abstracts presented during the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, held on June 4-8, 2021. Dr. Kevin Knopf from the University of California, San Francisco moderated the discussion between hematology KOLs Dr. Aaron Goodman from the University of California, San Diego and Dr. Jordan Gauthier from Fred Hutchinson Cancer Center.

The discussion covered ASCO abstract #7513 Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), ASCO abstract #7540: First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R‑CHOP in patients with newly diagnosed DLBCL, and ASCO abstract #7512 Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

Watch this video for the full discussion:

Our ASCO Panel Series covered six therapeutic areas including DLBCL. Click below to read more about them and watch their video analysis.

Breast Cancer


Gastrointestinal Cancer

Lung Cancer

Genitourinary Cancer

Download attached file

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.